Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC.

J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.

PMID:
28049011
2.

Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.

Alberice JV, Amaral AF, Armitage EG, Lorente JA, Algaba F, Carrilho E, Márquez M, García A, Malats N, Barbas C.

J Chromatogr A. 2013 Nov 29;1318:163-70. doi: 10.1016/j.chroma.2013.10.002. Epub 2013 Oct 4.

PMID:
24139504
3.

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Márquez M, Vazquez M, Lapi E, Castro-Giner F, Beltran S, Bayés M, Carrato A, Cigudosa JC, Domínguez O, Gut M, Herranz J, Juanpere N, Kogevinas M, Langa X, López-Knowles E, Lorente JA, Lloreta J, Pisano DG, Richart L, Rico D, Salgado RN, Tardón A, Chanock S, Heath S, Valencia A, Losada A, Gut I, Malats N, Real FX.

Nat Genet. 2013 Dec;45(12):1464-9. doi: 10.1038/ng.2799. Epub 2013 Oct 13.

4.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

PMID:
24018021
5.

ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.

Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A, Domínguez O, Pisano DG, Gómez G, Lloreta J, Lorente JA, Malats N, Real FX.

PLoS One. 2013 May 1;8(5):e62483. doi: 10.1371/journal.pone.0062483. Print 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/6e83489b-e1ff-4523-9b31-08c90fa39030.

6.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
7.

[Cystitis and ketamine associated bladder dysfunction].

García-Larrosa A, Castillo C, Ventura M, Lorente JA, Bielsa O, Arango O.

Actas Urol Esp. 2012 Jan;36(1):60-4. doi: 10.1016/j.acuro.2011.06.020. Epub 2011 Sep 28. Spanish.

PMID:
21955556
8.

Experience in the treatment of rectourethral fistulae after radical prostatectomy.

Lorente JA, Bielsa O, Rijo E, Francés A, Pera M, Arango O.

Arch Esp Urol. 2011 Jul;64(6):517-23. English, Spanish.

PMID:
21791718
9.

Clinical-pathological differences and smoking habit depending on gender in a cohort of patients with transitional cell carcinoma of the bladder: retrospective study.

Lorente JA, Bielsa O, Rijo E, Cortadellas R, Nohales G, Francés A, Juanpere N, Lloreta J, Arango O.

Arch Esp Urol. 2011 Jun;64(5):427-33. English, Spanish.

PMID:
21705815
10.

PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.

Agell L, Hernández S, Salido M, de Muga S, Juanpere N, Arumí-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J.

Mod Pathol. 2011 Mar;24(3):443-52. doi: 10.1038/modpathol.2010.208. Epub 2010 Nov 26.

11.

The use of tension-free vaginal tape associated with pelvic floor reconstructive surgery.

del Canto M, Bielsa O, Lorente JA, Castillo M, Carreras R, Arango O.

Actas Urol Esp. 2009 Nov;33(10):1097-102. English, Spanish.

PMID:
20096180
12.

FGFR3 mutations in prostate cancer: association with low-grade tumors.

Hernández S, de Muga S, Agell L, Juanpere N, Esgueva R, Lorente JA, Mojal S, Serrano S, Lloreta J.

Mod Pathol. 2009 Jun;22(6):848-56. doi: 10.1038/modpathol.2009.46. Epub 2009 Apr 17.

Supplemental Content

Loading ...
Support Center